Relutrigine

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Relutrigine ( ; developmental code name PRAX-562) is a persistent neuronal sodium channel blocker which is under development for the treatment of epilepsy and headache. It is taken orally. The drug shows anticonvulsant effects in animals but with improved tolerability compared to existing sodium channel blockers. Relutrigine is under development by Praxis Precision Medicines. As of May 2026, it is in preregistration for epilepsy. Conversely, no recent development has been reported for headaches.

Relutrigine ( ; developmental code name PRAX-562) is a persistent neuronal sodium channel blocker which is under development for the treatment of epilepsy and headache. It is taken orally. The drug shows anticonvulsant effects in animals but with improved tolerability compared to existing sodium channel blockers. Relutrigine is under development by Praxis Precision Medicines. As of May 2026, it is in preregistration for epilepsy. Conversely, no recent development has been reported for headaches.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1370309606 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.